Abstract It has been previously claimed that miconazole (MNZ) has activity against Plasmodium falciparum in vitro. Therefore, this study aims to evaluate the potential of MNZ as an alternative antimalarial… Click to show full abstract
Abstract It has been previously claimed that miconazole (MNZ) has activity against Plasmodium falciparum in vitro. Therefore, this study aims to evaluate the potential of MNZ as an alternative antimalarial agent. MNZ was entrapped in nanostructured lipid carriers (NLC) based on Softisan®154 and soybean oil admixtures. Batches of MNZ-loaded NLC were characterized for particle size and surface charge, differential scanning calorimetry (DSC), x-ray diffractometry (XRD), and encapsulation efficiency (EE%). In vitro release and in vivo antimalarial evaluations (using a murine model) were also carried out. Particle size of NLC ranged from 175 to 525 nm, and surface charge from −20 to −27 mV. DSC thermograms showed amorphization of MNZ at low melting points and enthalpies. X-ray diffractograms showed broader and weaker patterns with few characteristic peaks of MNZ, and high EE% of 90–98% were recorded. In vitro release study showed controlled release effect with about 82% of MNZ released after 8 h. In vivo clearance of parasitaemia was drug loading-dependent and compared favourably with the positive control. Stability testing of the MNZ-loaded NLC exhibited no significant (p > 0.05) changes in EE% compared to initial analysis. Thus, MNZ could be repurposed as an effective alternative for the treatment of malaria.
               
Click one of the above tabs to view related content.